Yeo Ilhwan, Wong Shing-Chiu, Mack Charles A, Ko Willis, Kim Luke K, Feldman Dmitriy N, Reisman Mark, Mick Stephanie L, Iannacone Erin M, Shah Tara, Bergman Geoffrey, Minutello Robert M
Division of Cardiology, Department of Medicine, Weill Cornell Medicine-NewYork-Presbyterian Hospital and Weill Cornell Cardiovascular Outcomes Research Group, New York, New York.
Department of Cardiothoracic Surgery, Weill Cornell Medical College, New York, New York.
J Soc Cardiovasc Angiogr Interv. 2023 Jun 29;2(5):101061. doi: 10.1016/j.jscai.2023.101061. eCollection 2023 Sep-Oct.
There are limited data on the feasibility of Impella-assisted percutaneous coronary intervention (PCI) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR).
To assess the feasibility of the Impella-assisted PCI in patients with severe symptomatic AS, we retrospectively reviewed the medical records to identify patients who were electively admitted for Impella-assisted PCI with a subsequent TAVR at Weill Cornell Medical Center from 2016 to 2021.
During the study period, 15 patients were identified to be eligible for the study, but the Impella failed to cross the aortic valve in 1 patient despite a concomitant balloon aortic valvuloplasty requiring a switch to an intra-aortic balloon pump to assist PCI. A total of 14 patients underwent successful PCI with the Impella CP and were included in the analysis. The median age was 89 years, and women accounted for 43% of the cohort. The median aortic valve area and mean gradient were 0.85 cm and 40 mm Hg, respectively, with a median left ventricular ejection fraction of 51%. The median SYNTAX score was 13. The left main stent was placed in 6 patients (43%), with a rotational atherectomy performed in 10 patients (71%). The balloon aortic valvuloplasty was performed in 2 patients before Impella placement. The TAVR was performed in all 14 patients on a median post-Impella-assisted PCI day of 25. No procedural complications were noted post-TAVR with no in-hospital or 30-day death.
In this single-center study of patients with severe AS, the elective Impella-assisted high-risk PCI was feasible and safe before TAVR in selected patients.
关于在接受经导管主动脉瓣置换术(TAVR)的严重主动脉瓣狭窄(AS)患者中使用Impella辅助进行经皮冠状动脉介入治疗(PCI)的可行性数据有限。
为评估Impella辅助PCI在有症状的严重AS患者中的可行性,我们回顾性审查了病历,以确定2016年至2021年在威尔康奈尔医学院因Impella辅助PCI并随后进行TAVR而择期入院的患者。
在研究期间,确定有15例患者符合研究条件,但尽管同时进行了球囊主动脉瓣成形术,仍有1例患者的Impella未能穿过主动脉瓣,需要改用主动脉内球囊泵来辅助PCI。共有14例患者使用Impella CP成功进行了PCI,并纳入分析。中位年龄为89岁,女性占队列的43%。主动脉瓣面积中位数和平均压差分别为0.85 cm²和40 mmHg,左心室射血分数中位数为51%。SYNTAX评分中位数为13。6例患者(43%)置入了左主干支架,10例患者(71%)进行了旋磨术。2例患者在放置Impella之前进行了球囊主动脉瓣成形术。所有14例患者均进行了TAVR,Impella辅助PCI后中位时间为25天。TAVR术后未发现手术并发症,无住院期间或30天死亡。
在这项针对严重AS患者的单中心研究中,对于选定患者,在TAVR之前进行择期Impella辅助的高危PCI是可行且安全的。